Paper40970519
The potential of phytomedicines to optimize CAR-T cell therapy in cancer.
Covo-Vergara Á and 8 others. Immunotherapy, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The potential of phytomedicines to optimize CAR-T cell therapy in cancer. Papers, record 40970519. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40970519
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy, Adoptive | Major topic |
| Neoplasms | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Phytochemicals | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Tumor Microenvironment | |
| Animals | |
| Adjuvants, Immunologic |
Source PubMed
References79
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37047272 | CAR T Cell Therapy: A Versatile Living Drug. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047272 | PubMed |
| 2 | 37834228 | Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834228 | PubMed |
| 3 | 37657771 | The Qi Yin San Liang San decoction enhances anti-CD19 CAR-T cell function in the treatment of B-cell lymphomas. | J Ethnopharmacol | 2024 | https://conductscience.org/library/papers/37657771 | PubMed |
| 4 | 36160152 | Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et). | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/36160152 | PubMed |
| 5 | 32433532 | A guide to cancer immunotherapy: from T cell basic science to clinical practice. | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/32433532 | PubMed |
| 6 | 22594470 | Pro-oxidant natural products as anticancer agents. | Curr Drug Targets | 2012 | https://conductscience.org/library/papers/22594470 | PubMed |
| 7 | 37696152 | Influence of the crystallinity on the physicochemical properties of spray-dried quercetin-inulin microparticles and their performance during in vitro digestion. | Food Chem | 2024 | https://conductscience.org/library/papers/37696152 | PubMed |
| 8 | 34751930 | Advances in plant-derived natural products for antitumor immunotherapy. | Arch Pharm Res | 2021 | https://conductscience.org/library/papers/34751930 | PubMed |
| 9 | 12553376 | Effect of piperine on the inhibition of lung metastasis induced B16F-10 melanoma cells in mice. | Clin Exp Metastasis | 2002 | https://conductscience.org/library/papers/12553376 | PubMed |
| 10 | 19017389 | Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells. | BMC Complement Altern Med | 2008 | https://conductscience.org/library/papers/19017389 | PubMed |
| 11 | 32354172 | Organic Acids from Roselle (Hibiscus sabdariffa L.)-A Brief Review of Its Pharmacological Effects. | Biomedicines | 2020 | https://conductscience.org/library/papers/32354172 | PubMed |
| 12 | 37670337 | Safety and efficacy of P2Et extract from Caesalpinia spinosa in breast cancer patients: study protocol for a randomized double blind phase II clinical trial (CS003-BC). | BMC Complement Med Ther | 2023 | https://conductscience.org/library/papers/37670337 | PubMed |
| 13 | 32878978 | Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32878978 | PubMed |
| 14 | 35814023 | Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. | Front Bioeng Biotechnol | 2022 | https://conductscience.org/library/papers/35814023 | PubMed |
| 15 | 29497610 | Cancer Chemoprevention and Piperine: Molecular Mechanisms and Therapeutic Opportunities. | Front Cell Dev Biol | 2018 | https://conductscience.org/library/papers/29497610 | PubMed |
| 16 | 33312174 | An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma. | Front Immunol | 2020 | https://conductscience.org/library/papers/33312174 | PubMed |
| 17 | 34568831 | Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. | Blood Cancer Discov | 2021 | https://conductscience.org/library/papers/34568831 | PubMed |
| 18 | 33552924 | Genotoxicity and mutagenicity assessment of a standardized extract (P2Et) obtained from Caesalpinia spinosa. | Toxicol Rep | 2021 | https://conductscience.org/library/papers/33552924 | PubMed |
| 19 | 37413990 | Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. | Cell | 2023 | https://conductscience.org/library/papers/37413990 | PubMed |
| 20 | 36358624 | Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36358624 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40970519
GET https://conductscience.org/api/papers/v1/40970519/references?page=2